Sardinia Leads the Charge: A New Integrated Approach to Cardiometabolic Health
A recent medical conference in Cagliari, Sardinia, has sparked a vital conversation about the future of cardiometabolic care. Bringing together institutional stakeholders, scientists, and patient representatives, the event – supported by Lilly – focused on building a comprehensive strategy to combat obesity, diabetes, and the rising concern of lipoprotein(a). This isn’t just a regional issue; it’s a microcosm of challenges facing healthcare systems globally.
The Rising Tide of Cardiometabolic Disease
Cardiometabolic diseases – conditions like heart disease, stroke, diabetes, and obesity – are reaching epidemic proportions worldwide. The World Health Organization estimates that over 422 million people globally have diabetes, and obesity rates continue to climb. In Italy, and particularly in regions like Sardinia, these numbers are especially concerning. A 2023 study published in The Lancet Regional Health – Europe highlighted a higher prevalence of obesity in Southern Italy compared to the national average, underscoring the need for targeted interventions.
Legislation and the Path to Integrated Care
The conference centered around Italy’s Law 149/2025 on Obesity and the National Chronic Disease Plan. These frameworks are pushing for a shift from fragmented care to integrated, patient-centered approaches. The key takeaway? Treating patients with multiple cardiometabolic conditions requires a holistic strategy, not just addressing individual symptoms. Riccardo Trentin, representing the Rete Sarda Diabete, emphasized this point, stating the need for multidisciplinary teams and comprehensive support networks.
Pro Tip: Don’t underestimate the power of patient education. Empowered patients are more likely to adhere to treatment plans and make positive lifestyle changes.
The Role of Community Pharmacies: A Growing Trend
A significant theme emerging from the discussions was the expanded role of community pharmacies. With over 600 pharmacies across Sardinia, they represent a readily accessible point of care. Marco Porcu of Federfarma highlighted their potential in providing health education, monitoring, and support for patients following Personalized Diagnostic Therapeutic Assistance (PDTA) plans. This aligns with a broader trend of utilizing pharmacies as integral parts of primary care networks, seen increasingly in countries like the UK and Australia.
Expanding Governance and the Importance of Mental Health
The call to broaden the regional diabetology consultation to include psychologists, pharmacists, and general practitioners signals a growing recognition of the complex interplay between physical and mental health. Obesity and diabetes are often linked to psychological factors like stress, anxiety, and depression. Addressing these issues is crucial for successful long-term management. Giovanni Fantola, from ARNAS Brotzu in Cagliari, rightly pointed out that obesity treatment must consider psychological and social aspects.
Lipoprotein(a): The Emerging Cardiometabolic Risk Factor
While obesity and diabetes are well-established risk factors, the conference also highlighted the growing awareness of lipoprotein(a) [Lp(a)]. This genetically determined lipid is increasingly recognized as a significant independent risk factor for cardiovascular disease. Recent research, including a 2023 study in the Journal of the American College of Cardiology, suggests that even individuals with normal cholesterol levels may be at increased risk if they have elevated Lp(a). This underscores the need for more widespread Lp(a) testing and targeted therapies.
Did you know? Lp(a) levels are largely determined by genetics and are relatively stable throughout life, making early identification crucial.
Prevention and Education: The Cornerstone of Success
Tatiana Lai of SIMDO emphasized the critical role of prevention and therapeutic education. Studies consistently demonstrate that educated patients experience fewer emergency visits and hospitalizations. Investing in preventative programs and empowering individuals to manage their health is not only clinically beneficial but also economically sound. This echoes the principles of value-based healthcare, which prioritizes outcomes and cost-effectiveness.
The Future of Cardiometabolic Care: Personalized and Predictive
Looking ahead, the future of cardiometabolic care will likely be characterized by:
- Personalized Medicine: Tailoring treatment plans based on individual genetic profiles, lifestyle factors, and disease characteristics.
- Predictive Analytics: Utilizing data analytics and artificial intelligence to identify individuals at high risk and intervene proactively.
- Digital Health Technologies: Leveraging wearable sensors, mobile apps, and telehealth platforms to monitor patients remotely and provide personalized support.
- Integrated Care Networks: Strengthening collaboration between primary care physicians, specialists, pharmacists, and other healthcare professionals.
FAQ
Q: What is Lipoprotein(a)?
A: Lipoprotein(a) is a genetically determined type of cholesterol that is an independent risk factor for cardiovascular disease.
Q: What is a PDTA plan?
A: PDTA stands for Personalized Diagnostic Therapeutic Assistance. It’s a care pathway designed to ensure patients receive coordinated and appropriate care.
Q: How can community pharmacies help with cardiometabolic health?
A: Pharmacies can provide health education, medication counseling, monitoring, and support for patients managing conditions like diabetes and obesity.
Explore further: Read our article on the latest advancements in diabetes technology or the impact of lifestyle interventions on heart health.
What are your thoughts on the future of cardiometabolic care? Share your comments below!
